Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 92


Tissue inhibitor of metalloproteinase-4 is elevated in early-stage breast cancers with accelerated progression and poor clinical course.

Liss M, Sreedhar N, Keshgegian A, Sauter G, Chernick MR, Prendergast GC, Wallon UM.

Am J Pathol. 2009 Sep;175(3):940-6. doi: 10.2353/ajpath.2009.081094. Epub 2009 Aug 21.


Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.

Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, Brünner N, Foekens JA.

Clin Cancer Res. 2004 Apr 1;10(7):2289-98.


Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade.

Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG.

Mod Pathol. 2007 Jan;20(1):84-9. Epub 2006 Nov 24.


Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure.

Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, Sauter G, Rimm DL, Magliocco AM, Rui H.

J Clin Oncol. 2011 Jun 20;29(18):2448-58. doi: 10.1200/JCO.2010.30.3552. Epub 2011 May 16.


Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.

Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, Xu XC.

Int J Cancer. 2008 May 1;122(9):2050-6. doi: 10.1002/ijc.23337.


Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

Breast Cancer Res. 2009;11(1):R11. doi: 10.1186/bcr2230. Epub 2009 Feb 24.


Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma.

Liu F, Cui L, Zhang Y, Chen L, Wang Y, Fan Y, Lei T, Gu F, Lang R, Pringle GA, Zhang X, Chen Z, Fu L.

Breast Cancer Res Treat. 2010 Dec;124(3):677-88. doi: 10.1007/s10549-010-0790-6. Epub 2010 Mar 9.


Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.

Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K.

Clin Cancer Res. 2003 Nov 1;9(14):5313-7.


Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer.

Schrohl AS, Christensen IJ, Pedersen AN, Jensen V, Mouridsen H, Murphy G, Foekens JA, Brunner N, Holten-Andersen MN.

Mol Cell Proteomics. 2003 Mar;2(3):164-72. Epub 2003 Apr 2.


The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.

Salvucci O, Bouchard A, Baccarelli A, Deschênes J, Sauter G, Simon R, Bianchi R, Basik M.

Breast Cancer Res Treat. 2006 Jun;97(3):275-83. Epub 2005 Dec 13.


[Relationship between the expression of matrix metalloproteinase-13 protein and other biomarkers, prognosis in invasive breast cancer].

Zhang B, Liu YX, Cao WF, Cao XC, Ning LS, Hao XS.

Zhonghua Bing Li Xue Za Zhi. 2008 Jul;37(7):471-6. Chinese.


Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.

Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Créme E, Wurtz A, Porte H, Huet G.

Cancer. 2005 Apr 15;103(8):1676-84.


Predictors of early distant metastasis in women with breast cancer.

Rosa Mendoza ES, Moreno E, Caguioa PB.

J Cancer Res Clin Oncol. 2013 Apr;139(4):645-52. doi: 10.1007/s00432-012-1367-z. Epub 2013 Jan 3.


Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.

Kim KJ, Huh SJ, Yang JH, Park W, Nam SJ, Kim JH, Lee JH, Kang SS, Lee JE, Kang MK, Park YJ, Nam HR.

Jpn J Clin Oncol. 2005 Mar;35(3):126-33.


Clinical significance of DJ-1 as a secretory molecule: retrospective study of DJ-1 expression at mRNA and protein levels in ductal carcinoma of the breast.

Tsuchiya B, Iwaya K, Kohno N, Kawate T, Akahoshi T, Matsubara O, Mukai K.

Histopathology. 2012 Jul;61(1):69-77. doi: 10.1111/j.1365-2559.2012.04202.x. Epub 2012 Mar 2.


Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.

Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM.

Clin Cancer Res. 2004 Nov 15;10(22):7621-8.


Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.

Spataro VJ, Litman H, Viale G, Maffini F, Masullo M, Golouh R, Martinez-Tello FJ, Grigolato P, Shilkin KB, Gusterson BA, Castiglione-Gertsch M, Price K, Lindtner J, Cortés-Funes H, Simoncini E, Byrne MJ, Collins J, Gelber RD, Coates AS, Goldhirsch A; International Breast Cancer Study Group.

Cancer. 2003 Apr 1;97(7):1591-600.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk